Welcome to our dedicated page for Covalon Technologies news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on Covalon Technologies stock.
Covalon Technologies Ltd. (CVALF) is described in its news releases as an advanced medical technologies and medical device company with expertise in advanced wound care, vascular access, and surgical consumables. The Covalon news flow often combines clinical, commercial, and financial updates, giving investors and healthcare professionals insight into how its technologies are being adopted and how the business is performing.
Recent announcements include detailed financial results, where the company has reported multiple years of revenue growth, profitability, and a debt-free balance sheet, as well as the declaration and payment of its first-ever special cash dividend. These financial updates are accompanied by commentary on revenue by product category and sales channel, including U.S. Vascular Access and Surgical Consumables, U.S. Advanced Wound Care, and International channels.
Covalon’s news also highlights clinical milestones and conference activity. The company has announced a peer-reviewed study in the Journal of the Association for Vascular Access evaluating its VALGuard ae Vascular Access Line Guard in pediatric central line care, with reported reductions in CLABSI rates. It regularly reports on participation in major professional meetings such as the Association for Vascular Access Annual Scientific Meeting, the Association of Pediatric Hematology/Oncology Nurses Conference, and the ANCC National Magnet & Pathway to Excellence Conference, where it showcases VALGuard ae, CovaClear ae, IV Clear ae, and SurgiClear ae dressings.
Investors following CVALF news can expect updates on quarterly and annual financial results, dividend decisions, board and executive changes, new clinical evidence, health economic findings, and Covalon’s presence at investor conferences such as the Planet MicroCap Showcase. This combination of financial, clinical, and market-facing news provides context on how the company positions its technologies and on the evolution of its business across its key sales channels.
Covalon Technologies (TSXV: COV; OTCQX: CVALF), a medical technologies company, has scheduled the release of its Q2 Fiscal 2025 financial results for Wednesday, May 28, 2025, before markets open. The company will host a conference call and webcast at 8:30am ET on the same day to discuss the results.
Investors can participate through the webcast or by dialing into the conference call using the following numbers: North American Toll-Free: 1-800-549-8228, Toronto Local: 289-819-1520, or New York Local: 646-564-2877 (Conference ID: 92114). A recording will be available on Covalon's website, and financial statements can be accessed through SEDAR PLUS.
Covalon Technologies Ltd. (CVALF) has announced the promotion of Kim Crooks to Chief Operating Officer (COO) and her appointment to the company's Board of Directors, effective immediately. Crooks, who rejoined Covalon in early 2024 as Senior Vice President – Operations, previously served as Vice President of Operations from 2012 to 2022. In her role, she has been overseeing production, operations, Quality Assurance, Quality Control, Regulatory Affairs, and Human Resources.
As part of her appointment, Crooks will receive 150,000 stock options vesting equally over three years at market price. Both her Board appointment and stock option grant are subject to TSX Venture Exchange approval.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 6, 2025, at 2:30 pm ET. CEO Brent Ashton will lead the presentation in Room 104 B at the Metro Toronto Convention Centre.
The presentation will focus on Covalon's mission to prevent healthcare complications through patient-centered technologies. Ashton will discuss the company's strong financial position and growth drivers. The conference, running May 5-6, 2025, provides a platform for healthcare companies and investors to connect.
Investors can register for one-on-one meetings with Covalon's management. Those unable to attend can learn more about Covalon's solutions through their website and social media channels including LinkedIn, Facebook, Instagram, and X.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) announced its participation in the Planet MicroCap Showcase: VEGAS 2025, scheduled for April 23, 2025, at 4:30 pm PST. CEO Brent Ashton will present the company's position as an undervalued, cash-rich healthcare company in the microcap sector.
Key highlights include:
- Strong financial position with over $17 million CAD cash, debt-free status, and consistent profitability
- Recognition as a 2025 OTCQX Best 50 Company and TSX Venture Top 50 company
- Focus on advanced wound care, vascular access, and surgical products
- Growing sales driven by healthcare provider and patient advocacy
The presentation will be accessible via webcast, with opportunities for 1x1 investor meetings at the Paris Hotel & Casino in Las Vegas.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has announced a significant competitive advantage following the April 2, 2025 US tariff announcements. The company's Canadian-manufactured medical products qualify for complete exemption from US tariffs under the United States-Mexico-Canada Agreement (USMCA) rules of origin requirements.
As the largest advanced wound care collagen dressing manufacturer in North America, Covalon stands to benefit substantially as competitors from the UK, Germany, and China face tariffs of 10%, 20%, and 54% respectively. The company maintains manufacturing operations in both Canada and the United States for its medical products, enabling it to maintain competitive pricing and uninterrupted access to the US market.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) held its Fiscal 2024 Annual Meeting of Shareholders on March 19, 2025. The meeting saw shareholders voting in favor of all proposed items, including the election of the Board of Directors and appointment of auditors.
The meeting achieved a 40.839% participation rate, with 11,189,231 shares represented either in person or by proxy. Detailed voting results will be available on SEDAR+, and management's presentation can be accessed through Covalon's investor relations website.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has announced its annual shareholder meeting scheduled for March 19, 2025, at 2:00pm Eastern Time. The meeting will be held in a virtual-only format, featuring a presentation from newly appointed CEO Brent Ashton, followed by a Q&A session.
Shareholders can attend via live webcast at https://virtual-meetings.tsxtrust.com/en/1738 using Meeting ID 1738 and password 'covalon2025'. Registered shareholders and appointed proxyholders will have full participation rights, including voting capabilities. Non-registered shareholders must complete additional steps to vote, including self-appointment as proxyholder and registration with TSX Trust Company.